Subjects: Cost-Benefit Analysis and Hepatitis C, Chronic -- drug therapy / Authors: Ollendorf, Daniel A., author - Digital Collections - National Library of Medicine Search Results

Start Over Subjects Cost-Benefit Analysis ✖ Subjects Hepatitis C, Chronic -- drug therapy ✖ Authors Ollendorf, Daniel A., author ✖

1. The comparative clinical effectiveness and value of simeprevir and sofosbuvir in the treatment of chronic hepatitis C infection: a technology assessment : final report

Author(s):: Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Pearson, Steven D., author
Publication:: [Boston, MA] : Institute for Clinical and Economic Review, April 15, 2014
Subject(s):: Comparative Effectiveness Research
Hepatitis C, Chronic -- drug therapy
Heterocyclic Compounds, 3-Ring -- therapeutic use
Sulfonamides -- therapeutic use
Uridine Monophosphate -- analogs & derivatives
Uridine Monophosphate -- therapeutic use
Antiviral Agents -- economics
Antiviral Agents -- therapeutic use
Cost-Benefit Analysis
Drug Costs
Drug Therapy, Combination
Genotype
Hepatitis C -- economics
Hepatitis C -- genetics
Heterocyclic Compounds, 3-Ring -- adverse effects
Heterocyclic Compounds, 3-Ring -- economics
Insurance Coverage
Interferon-alpha -- therapeutic use
Oligopeptides -- therapeutic use
Polyethylene Glycols -- therapeutic use
Proline -- analogs & derivatives
Proline -- therapeutic use
Protease Inhibitors -- economics
Protease Inhibitors -- therapeutic use
Randomized Controlled Trials as Topic
Ribavirin -- therapeutic use
Sulfonamides -- adverse effects
Technology Assessment, Biomedical
Treatment Outcome
Uridine Monophosphate -- adverse effects
Uridine Monophosphate -- economics
Value-Based Purchasing
Humans
United States